| |
INSTI, Dolutegravir & Hypertension, Diabetes
|
| |
| |
There is a long history of research in this area, here are many such studies with mixed results, some finding an association of DTG with diabetes or hypertension incidence, others like the large one at IAS 2023 finding there was no association, with some finding weight gain could be the mediator.
There are 2 studies now LANCET HIV just published on this subject & an Editorial, here they are AND a history of such studies.
PRIOR STUDIES
ACTG CROI 2020
Integrase Inhibitors Tied to Lower Risk of Progression from Prediabetes to Diabetes - HAILO
at IAS 2023
no association: Evaluation of Incident Hypertension and Blood Pressure Changes Among People Living With HIV-1 (PLWH) Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Randomized Clinical Trials Through 96 Weeks
EACS 2023
BICTEGRAVIR and DOLUTEGRAVIR have no impact on glucose levels 12 months after initiation
published in 2024
Conclusions. Initiating first cART regimens with INSTIs or PIs vs NNRTIs may confer greater risk of DM, likely mediated
through weight gain (NA-ACCORD) When accounting for potential mediation of the relationship between cART exposure
and incident DM by 12-month weight change, our analyses revealed attenuation of the total effect of INSTI initiation on incident DM by an absolute amount of 5%. This indicates a residual elevated risk of DM associated with INSTI use of 3% that was unexplained by 12-month weight, though both reduced and increased risks were plausible inferences.. https://www.natap.org/2024/HIV/ciaa1403.pdf
IAS 2025
Exploring the relationship between dolutegravir and diabetes using programmatic data in a cohort of ART clients in Lubombo and Manzini
at CROI 2026
Hypertension Risk in a Large Cohort of People Living With HIV After a Switch to Dolutegravir - (03/01/26)
Hypertension Risk in a Large Cohort of People Living With HIV After a Switch to Dolutegravir - (03/01/26)
Two Years of Dolutegravir (DTG) Use Did Not Affect Body Composition in People Without HIV Infection - (03/01/26)
Lancet HIV Comment March 27, 2026
Metabolic syndrome and cardiovascular risk on INSTIs
Download the PDF here
March 27, 2026
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE
Download the PDF here
Download the PDF here
March 27, 202
Incident diabetes after switching to integrase strand transfer inhibitors in people with HIV in the USA and Canada: a cohort study
Download the PDF here
|
|
| |
| |
|
|
|
